PT  - JOURNAL ARTICLE
AU  - MITSUHIRO FURUTA
AU  - JUNICHIRO WATANABE
AU  - TAKESHI ARAMAKI
AU  - AKIFUMI NOTSU
AU  - HIROFUMI YASUI
TI  - Hepatic Arterial Infusion Chemotherapy for Metastatic Breast Cancer Patients With Resistance to Standard Systemic Chemotherapies
AID  - 10.21873/invivo.11771
DP  - 2020 Jan 01
TA  - In Vivo
PG  - 275--282
VI  - 34
IP  - 1
4099  - http://iv.iiarjournals.org/content/34/1/275.short
4100  - http://iv.iiarjournals.org/content/34/1/275.full
SO  - In Vivo2020 Jan 01; 34
AB  - Background/Aim: Hepatic arterial infusion chemotherapy (HAIC) is a treatment option for metastatic breast cancer (MBC) patients with extensive liver metastasis (LM); however, the appropriate regimen and the treatment effects have not been discussed. The aim of this study is to evaluate the efficacy and safety of HAIC with the 5-FU, epirubicin, and mitomycin-C (FEM) regimen. Patients and Methods: We reviewed MBC patients with critical LM who were resistant to standard systemic chemotherapies and had received HAIC with an FEM regimen. Results: We identified 57 patients who received HAIC between 2003 and 2017. The patient characteristics were as follows: i) median age=56 (30-80), and ii) Eastern Cooperative Oncology Group Performance Status, 0/1/2=43/11/3. The median number of LMs was 8 (range 1 to ≥20), the median diameter of LM was 5.2 cm (range=1.6 to 20.1). The median overall survival from the initiation of HAIC was 11.3 months (95% confidence interval=8.5-15.6). The objective response rate of LM was 63%. Conclusion: HAIC with an FEM regimen is an effective salvage treatment for MBC patients with advanced LM.